Core Laboratories N.V.
Bear Case (25th pct.)
-55.8% vs price
Base Case (Median)
-45.5% vs price
Bull Case (75th pct.)
-13.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-1.04 | -108.2% | High (40%) |
| PE Comparable | $6.88 | -45.5% | Medium (25%) |
| Growth Trajectory DCF | $13.43 | 6.4% | Medium (20%) |
| Graham Number | $8.49 | -32.7% | Medium (40%) |
| EV/EBITDA | $15.29 | 21.2% | Medium (20%) |
| EV/FCF | $4.62 | -63.4% | Medium (20%) |
| Earnings Power Value | $6.54 | -48.2% | Medium (50%) |
Based on 7 out of 8 methods, CLB appears overvalued at the current price of $12.62. The base case fair value of $6.88 implies 45.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.